Exact Sciences (EXAS) Stock Forecast, Price Target & Predictions
EXAS Stock Forecast
Exact Sciences stock forecast is as follows: an average price target of $94.33 (represents a 38.74% upside from EXAS’s last price of $67.99) and a rating consensus of 'Buy', based on 17 wall street analysts offering a 1-year stock forecast.
EXAS Price Target
The average price target for Exact Sciences (EXAS) is $94.33 based on 1-year price targets from 17 Wall Street analysts in the past 3 months, with a price target range of $168.00 to $60.00. This represents a potential 38.74% upside from EXAS's last price of $67.99.
EXAS Analyst Ratings
According to 17 Wall Street analysts, Exact Sciences's rating consensus is 'Buy'. The analyst rating breakdown for EXAS stock is 1 'Strong Buy' (5.88%), 15 'Buy' (88.24%), 1 'Hold' (5.88%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Exact Sciences Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 16, 2024 | Mark Massaro | BTIG | $82.00 | $69.48 | 18.02% | 20.61% |
| Sep 16, 2024 | Patrick Donnelly | Citigroup | $80.00 | $67.90 | 17.82% | 17.66% |
| Sep 13, 2024 | Kyle Mikson | Canaccord Genuity | $75.00 | $67.39 | 11.29% | 10.31% |
| Sep 12, 2024 | David Westenberg | Piper Sandler | $85.00 | $66.93 | 27.00% | 25.02% |
| Jul 19, 2024 | David Westenberg | Piper Sandler | $80.00 | $46.81 | 70.90% | 17.66% |
| Jun 26, 2024 | Sung Ji Nam | Scotiabank | $70.00 | $44.16 | 58.51% | 2.96% |
| Jun 26, 2024 | Mark Massaro | BTIG | $70.00 | $41.37 | 69.20% | 2.96% |
| Jun 03, 2024 | Tycho Peterson | Jefferies | $75.00 | $45.45 | 65.02% | 10.31% |
| May 09, 2024 | Kyle Mikson | Canaccord Genuity | $85.00 | $59.48 | 42.91% | 25.02% |
| Jun 22, 2023 | Patrick Donnelly | Citigroup | $130.00 | $94.58 | 37.45% | 91.20% |
The latest Exact Sciences stock forecast, released on Sep 16, 2024 by Mark Massaro from BTIG, set a price target of $82.00, which represents a 18.02% increase from the stock price at the time of the forecast ($69.48), and a 20.61% increase from EXAS last price ($67.99).
Exact Sciences Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 4 | 7 | 9 |
| Avg Price Target | $80.50 | $77.43 | $78.00 |
| Last Closing Price | $67.99 | $67.99 | $67.99 |
| Upside/Downside | 18.40% | 13.88% | 14.72% |
In the current month, the average price target of Exact Sciences stock is $80.50, according to 4 Wall Street analysts offering twelve months forecast. The average price target represents a 18.40% increase as opposed to Exact Sciences's last price of $67.99. This month's average price target is up 3.96% compared to last quarter, and up 3.21% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 16, 2024 | BTIG | Buy | Buy | Hold |
| Sep 16, 2024 | Citigroup | Buy | Buy | Hold |
| Sep 13, 2024 | Canaccord Genuity | Buy | Buy | Hold |
| Sep 12, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Sep 12, 2024 | Evercore ISI | Outperform | Outperform | Hold |
| Aug 27, 2024 | Wells Fargo | Equal-Weight | Overweight | Initialise |
| Aug 01, 2024 | Benchmark | Buy | Buy | Hold |
| Jul 19, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Jun 26, 2024 | Scotiabank | Outperform | Sector Outperform | Initialise |
| Jun 26, 2024 | Scotiabank | - | Outperform | Initialise |
Exact Sciences's last stock rating was published by BTIG on Sep 16, 2024. The company gave EXAS a "Buy" rating, the same as its previous rate.
Exact Sciences Financial Forecast
Exact Sciences Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $628.34M | $622.09M | $602.45M | $553.00M | $523.07M | - | $521.64M | $486.57M | $473.81M | $456.38M | $434.82M | $402.08M | $466.34M | $408.36M | $268.87M | $347.82M | $295.57M |
| Avg Forecast | $978.12M | $912.09M | $891.82M | $833.53M | $870.34M | $815.33M | $793.44M | $737.19M | $777.35M | $717.15M | $690.02M | $627.35M | $638.83M | $616.79M | $601.14M | $543.45M | $527.21M | $501.70M | $498.99M | $498.99M | $463.11M | $449.11M | $430.03M | $420.98M | $388.57M | $443.96M | $337.43M | $228.42M | $349.13M | $297.43M |
| High Forecast | $1.00B | $933.42M | $912.67M | $853.01M | $890.69M | $834.39M | $811.99M | $754.42M | $795.52M | $720.03M | $706.16M | $642.02M | $654.37M | $624.98M | $615.19M | $556.16M | $539.54M | $513.43M | $498.99M | $519.50M | $482.14M | $467.57M | $447.70M | $438.28M | $404.54M | $462.20M | $351.30M | $237.81M | $363.48M | $309.65M |
| Low Forecast | $965.99M | $900.78M | $880.75M | $823.19M | $859.54M | $805.22M | $783.60M | $728.04M | $767.71M | $714.54M | $681.46M | $619.57M | $631.20M | $609.68M | $593.68M | $536.71M | $520.67M | $495.48M | $498.99M | $489.89M | $454.66M | $440.92M | $422.19M | $413.30M | $381.48M | $435.86M | $331.28M | $224.26M | $342.77M | $292.00M |
| # Analysts | 9 | 9 | 9 | 9 | 13 | 13 | 13 | 13 | 7 | 15 | 7 | 4 | 7 | 17 | 8 | 8 | 7 | 7 | 13 | 13 | 7 | 15 | 8 | 10 | 7 | 7 | 8 | 7 | 10 | 9 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.02% | 1.03% | 1.11% | 1.05% | 1.04% | - | 1.05% | 1.05% | 1.05% | 1.06% | 1.03% | 1.03% | 1.05% | 1.21% | 1.18% | 1.00% | 0.99% |
Exact Sciences's average Quarter revenue forecast for Dec 23 based on 7 analysts is $638.83M, with a low forecast of $631.20M, and a high forecast of $654.37M. EXAS's average Quarter revenue forecast represents a 1.67% increase compared to the company's last Quarter revenue of $628.34M (Sep 23).
Exact Sciences EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 13 | 13 | 13 | 13 | 7 | 15 | 7 | 4 | 7 | 17 | 8 | 8 | 7 | 7 | 13 | 13 | 7 | 15 | 8 | 10 | 7 | 7 | 8 | 7 | 10 | 9 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $72.03M | $-76.93M | $-54.52M | $-92.54M | $-84.99M | - | $-102.56M | $-130.75M | $-176.51M | $-121.36M | $-124.34M | $-225.66M | $-375.24M | $-158.79M | $-24.18M | $-51.71M | $-66.92M |
| Avg Forecast | $-237.66M | $-221.62M | $-216.69M | $-202.53M | $-211.47M | $-198.10M | $-192.79M | $-179.12M | $-188.88M | $-174.25M | $-167.66M | $-164.50M | $-155.22M | $-149.86M | $-146.06M | $-149.54M | $-128.10M | $-121.50M | $-121.24M | $-126.58M | $-135.95M | $-135.78M | $-110.45M | $-77.89M | $-370.69M | $-3.61B | $-128.26M | $-26.10M | $-41.19M | $-213.39M |
| High Forecast | $-234.71M | $-218.87M | $-214.00M | $-200.01M | $-208.85M | $-195.65M | $-190.39M | $-176.90M | $-186.53M | $-173.61M | $-165.58M | $-131.60M | $-153.37M | $-148.14M | $-144.25M | $-119.63M | $-126.51M | $-97.20M | $-121.24M | $-101.27M | $-108.76M | $-108.62M | $-88.36M | $-62.31M | $-296.55M | $-2.89B | $-102.60M | $-20.88M | $-32.95M | $-170.71M |
| Low Forecast | $-243.21M | $-226.80M | $-221.75M | $-207.26M | $-216.41M | $-202.74M | $-197.29M | $-183.31M | $-193.29M | $-174.95M | $-171.58M | $-197.39M | $-159.00M | $-151.85M | $-149.48M | $-179.45M | $-131.09M | $-145.80M | $-121.24M | $-151.90M | $-163.14M | $-162.94M | $-132.54M | $-93.46M | $-444.83M | $-4.33B | $-153.91M | $-31.32M | $-49.43M | $-256.07M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.48% | 0.53% | 0.36% | 0.72% | 0.70% | - | 0.81% | 0.96% | 1.30% | 1.10% | 1.60% | 0.61% | 0.10% | 1.24% | 0.93% | 1.26% | 0.31% |
7 analysts predict EXAS's average Quarter EBITDA for Dec 23 to be $-155.22M, with a high of $-153.37M and a low of $-159.00M. This is -315.50% lower than Exact Sciences's previous annual EBITDA (Sep 23) of $72.03M.
Exact Sciences Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 13 | 13 | 13 | 13 | 7 | 15 | 7 | 4 | 7 | 17 | 8 | 8 | 7 | 7 | 13 | 13 | 7 | 15 | 8 | 10 | 7 | 7 | 8 | 7 | 10 | 9 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $794.00K | $-81.03M | $-74.15M | $-127.75M | $-148.76M | - | $-166.06M | $-180.94M | $-220.61M | $-166.94M | $-176.91M | $-31.16M | $-436.81M | $-219.88M | $-86.14M | $-105.70M | $77.94M |
| Avg Forecast | $86.19M | $54.72M | $56.72M | $-5.02M | $36.01M | $14.75M | $9.34M | $-32.53M | $-12.67M | $-35.88M | $-62.73M | $-225.07M | $-77.95M | $-86.90M | $-87.51M | $-204.61M | $-146.41M | $-167.13M | $-189.82M | $-186.24M | $-186.01M | $-169.70M | $-151.93M | $-110.82M | $-51.19M | $-4.20B | $-177.60M | $-92.98M | $-84.20M | $248.53M |
| High Forecast | $88.81M | $56.39M | $58.44M | $-4.94M | $37.10M | $15.20M | $9.63M | $-32.01M | $-12.47M | $-26.91M | $-61.72M | $-180.06M | $-72.07M | $-59.74M | $-86.10M | $-163.69M | $-144.04M | $-133.70M | $-189.82M | $-148.99M | $-148.81M | $-135.76M | $-121.55M | $-88.65M | $-40.95M | $-3.36B | $-142.08M | $-74.38M | $-67.36M | $298.24M |
| Low Forecast | $84.80M | $53.84M | $55.80M | $-5.17M | $35.43M | $14.51M | $9.19M | $-33.52M | $-13.06M | $-52.02M | $-64.64M | $-270.09M | $-91.19M | $-119.48M | $-90.17M | $-245.53M | $-150.85M | $-200.55M | $-189.82M | $-223.49M | $-223.21M | $-203.64M | $-182.32M | $-132.98M | $-61.43M | $-5.04B | $-213.12M | $-111.57M | $-101.04M | $198.83M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.01% | 0.93% | 0.36% | 0.87% | 0.89% | - | 0.89% | 0.97% | 1.30% | 1.10% | 1.60% | 0.61% | 0.10% | 1.24% | 0.93% | 1.26% | 0.31% |
Exact Sciences's average Quarter net income forecast for Dec 23 is $-77.95M, with a range of $-91.19M to $-72.07M. EXAS's average Quarter net income forecast represents a -9917.57% decrease compared to the company's last Quarter net income of $794.00K (Sep 23).
Exact Sciences SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 13 | 13 | 13 | 13 | 7 | 15 | 7 | 4 | 7 | 17 | 8 | 8 | 7 | 7 | 13 | 13 | 7 | 15 | 8 | 10 | 7 | 7 | 8 | 7 | 10 | 9 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $390.55M | $414.45M | $404.26M | $404.11M | $379.70M | - | $397.60M | $401.98M | $463.71M | $383.12M | $362.43M | $453.84M | $312.21M | $252.08M | $225.60M | $281.70M | $264.10M |
| Avg Forecast | $764.76M | $713.13M | $697.28M | $651.70M | $680.49M | $637.48M | $620.36M | $576.38M | $607.78M | $560.71M | $539.50M | $500.03M | $499.48M | $482.24M | $470.01M | $454.58M | $412.21M | $383.55M | $390.15M | $445.91M | $413.25M | $356.70M | $348.68M | $227.02M | $303.81M | $347.12M | $203.60M | $178.60M | $224.41M | $232.55M |
| High Forecast | $782.64M | $729.80M | $713.58M | $666.94M | $696.39M | $652.38M | $634.87M | $589.86M | $621.99M | $562.97M | $552.12M | $600.04M | $511.63M | $488.65M | $480.99M | $545.49M | $421.85M | $460.26M | $390.15M | $535.09M | $495.90M | $428.04M | $418.42M | $272.42M | $316.29M | $361.38M | $244.32M | $185.94M | $269.29M | $242.11M |
| Low Forecast | $755.27M | $704.28M | $688.63M | $643.62M | $672.04M | $629.57M | $612.67M | $569.23M | $600.24M | $558.67M | $532.81M | $400.03M | $493.51M | $476.68M | $464.18M | $363.66M | $407.09M | $306.84M | $390.15M | $356.73M | $330.60M | $285.36M | $278.94M | $181.62M | $298.27M | $340.78M | $162.88M | $175.34M | $179.52M | $228.31M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.81% | 0.88% | 0.89% | 0.98% | 0.99% | - | 0.89% | 0.97% | 1.30% | 1.10% | 1.60% | 1.49% | 0.90% | 1.24% | 1.26% | 1.26% | 1.14% |
Exact Sciences's average Quarter SG&A projection for Dec 23 is $499.48M, based on 7 Wall Street analysts, with a range of $493.51M to $511.63M. The forecast indicates a 27.89% rise compared to EXAS last annual SG&A of $390.55M (Sep 23).
Exact Sciences EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 13 | 13 | 13 | 13 | 7 | 15 | 7 | 4 | 7 | 17 | 8 | 8 | 7 | 7 | 13 | 13 | 7 | 15 | 8 | 10 | 7 | 7 | 8 | 7 | 10 | 9 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.45 | $-0.42 | $-0.72 | $-0.84 | - | $-0.94 | $-1.04 | $-1.28 | $-0.97 | $-1.03 | $-0.18 | $-2.79 | $-1.46 | $-0.58 | $-0.71 | $0.56 |
| Avg Forecast | $0.47 | $0.30 | $0.31 | $-0.03 | $0.20 | $0.08 | $0.05 | $-0.18 | $-0.07 | $-0.19 | $-0.34 | $-0.47 | $-0.42 | $-0.47 | $-0.47 | $-0.73 | $-0.79 | $-1.07 | $-1.04 | $-1.04 | $-1.10 | $-0.84 | $-0.85 | $-0.75 | $-0.96 | $-0.19 | $-0.54 | $-0.65 | $-0.58 | $-0.35 |
| High Forecast | $0.48 | $0.31 | $0.32 | $-0.03 | $0.20 | $0.08 | $0.05 | $-0.17 | $-0.07 | $-0.15 | $-0.33 | $-0.47 | $-0.39 | $-0.32 | $-0.47 | $-0.71 | $-0.78 | $-1.06 | $-1.04 | $-1.02 | $-1.07 | $-0.82 | $-0.83 | $-0.73 | $-0.94 | $-0.19 | $-0.52 | $-0.63 | $-0.57 | $-0.35 |
| Low Forecast | $0.46 | $0.29 | $0.30 | $-0.03 | $0.19 | $0.08 | $0.05 | $-0.18 | $-0.07 | $-0.28 | $-0.35 | $-0.49 | $-0.49 | $-0.65 | $-0.49 | $-0.75 | $-0.82 | $-1.11 | $-1.04 | $-1.10 | $-1.16 | $-0.88 | $-0.89 | $-0.79 | $-1.02 | $-0.20 | $-0.56 | $-0.68 | $-0.61 | $-0.37 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.01% | 0.95% | 0.58% | 0.91% | 0.78% | - | 0.90% | 0.95% | 1.52% | 1.15% | 1.38% | 0.19% | 14.41% | 2.73% | 0.90% | 1.22% | -1.58% |
According to 7 Wall Street analysts, Exact Sciences's projected average Quarter EPS for Dec 23 is $-0.42, with a low estimate of $-0.49 and a high estimate of $-0.39. This represents a -9712.05% decrease compared to EXAS previous annual EPS of - (Sep 23).
Exact Sciences Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| GH | Guardant Health | $25.09 | $57.27 | 128.26% | Buy |
| ILMN | Illumina | $130.21 | $200.82 | 54.23% | Buy |
| CRL | Charles River Laboratories | $206.21 | $316.29 | 53.38% | Buy |
| EXAS | Exact Sciences | $67.99 | $94.33 | 38.74% | Buy |
| CSTL | Castle Biosciences | $31.25 | $38.00 | 21.60% | Buy |
| DHR | Danaher | $272.47 | $313.59 | 15.09% | Buy |
| TMO | Thermo Fisher Scientific | $610.49 | $646.32 | 5.87% | Buy |
| A | Agilent | $138.35 | $144.90 | 4.73% | Buy |
| CDNA | CareDx | $30.12 | $31.00 | 2.92% | Buy |
| MYGN | Myriad Genetics | $28.60 | $27.67 | -3.25% | Hold |
| NTRA | Natera | $127.21 | $114.38 | -10.09% | Buy |
| TWST | Twist Bioscience | $47.67 | $42.40 | -11.06% | Buy |
EXAS Forecast FAQ
Is Exact Sciences a good buy?
Yes, according to 17 Wall Street analysts, Exact Sciences (EXAS) is considered a 'Buy'. The rating consensus is based on 1 'Strong Buy' and 15 'Buy' recommendations, accounting for 94.12% of EXAS's total ratings.
What is EXAS's price target?
Exact Sciences (EXAS) average price target is $94.33 with a range of $60 to $168, implying a 38.74% from its last price of $67.99. The data is based on 17 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Exact Sciences stock go up soon?
According to Wall Street analysts' prediction for EXAS stock, the company can go up by 38.74% (from the last price of $67.99 to the average price target of $94.33), up by 147.10% based on the highest stock price target, and down by -11.75% based on the lowest stock price target.
Can Exact Sciences stock reach $100?
EXAS's highest twelve months analyst stock price target of $168 supports the claim that Exact Sciences can reach $100 in the near future.
What is Exact Sciences's current price target trend?
4 Wall Street analysts forecast a $80.5 price target for Exact Sciences (EXAS) this month, up 18.40% from its last price of $67.99. Compared to the last 3 and 12 months, the average price target increased by 13.88% and increased by 14.72%, respectively.
What are Exact Sciences's analysts' financial forecasts?
Exact Sciences's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $3.22B (high $3.29B, low $3.18B), average EBITDA is $-781M (high $-772M, low $-800M), average net income is $27.57M (high $29.92M, low $25.61M), average SG&A $2.51B (high $2.57B, low $2.48B), and average EPS is $0.15 (high $0.162, low $0.139). EXAS's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $3.62B (high $3.7B, low $3.57B), average EBITDA is $-878M (high $-868M, low $-899M), average net income is $192.61M (high $198.7M, low $189.27M), average SG&A $2.83B (high $2.89B, low $2.79B), and average EPS is $1.05 (high $1.08, low $1.03).
Did the EXAS's actual financial results beat the analysts' financial forecasts?
Based on Exact Sciences's last annual report (Dec 2022), the company's revenue was $2.08B, which missed the average analysts forecast of $2.49B by -16.29%. Apple's EBITDA was $-480M, missing the average prediction of $-633M by -24.20%. The company's net income was $-624M, missing the average estimation of $-876M by -28.79%. Apple's SG&A was $1.58B, missing the average forecast of $2.05B by -22.58%. Lastly, the company's EPS was $-3.54, missing the average prediction of $-5.047 by -29.85%. In terms of the last quarterly report (Sep 2023), Exact Sciences's revenue was $628.34M, beating the average analysts' forecast of $616.79M by 1.87%. The company's EBITDA was $72.03M, missing the average prediction of $-150M by -148.06%. Exact Sciences's net income was $794K, missing the average estimation of $-86.896M by -100.91%. The company's SG&A was $390.55M, missing the average forecast of $482.24M by -19.01%. Lastly, the company's EPS was $0.0044, missing the average prediction of $-0.471 by -100.93%